5:32 PM
 | 
Dec 19, 2012
 |  BC Extra  |  Clinical News

Amicus, GSK Fabry's compound misses in Phase III trial

Amicus Therapeutics Inc. (NASDAQ:FOLD) and partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said late Wednesday that Amigal migalastat missed the primary endpoint in the Phase III FACETS (Study 011) trial to treat Fabry's disease. Amicus was up $0.11 to $5.77 on Wednesday. In early after...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >